ANRO – alto neuroscience, inc. (US:NASDAQ)
Stock Stats
News
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions [Yahoo! Finance]
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
Alto Neuroscience, Inc. (NYSE: ANRO) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $32.00 price target on the stock.
Form 4 Alto Neuroscience, Inc. For: Mar 28 Filed by: Smith Nicholas Conrad
Form SC 13G Alto Neuroscience, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Form 10-K Alto Neuroscience, Inc. For: Dec 31
Form 8-K Alto Neuroscience, Inc. For: Mar 21
Form 4 Alto Neuroscience, Inc. For: Mar 08 Filed by: Radhakrishnan Maha
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.